Melanoma

for medical students: what you need to know, from skin basics to treatment in psoriasis and melanoma, managing uncertainty  

Uveal melanoma is a rare but very aggressive malignancy: independently of the currently available therapies, 50 % of patients will develop metastasis and median survival time of these patients is only less than 8 months.  

Skin cancer is the most common malignancy – and the incidence is increasing rapidly In the last 10 years, the incidence in the UK has doubled Responsible for 2% of cancer deaths each year 80% of these are melanoma   General Risk Factors Age Sun bed use Fair skin Hx of sunburn Hx of living overseas FH Occupations – outdoors – e.g. bricklayer  

A report warns that continued use of sunbeds could be a key factor in a sharp increase in the rate of skin cancer in Scotland.  

Data sources PubMed, ISI Web of Science (Science Citation Index Expanded), Embase, Pascal, Cochrane Library, LILACS, and MedCarib, along with published surveys reporting prevalence of sunbed use at national level in Europe.  

Risk Factor of BRCA1 with family history. First degree relatives - A male in one family dies of peritoneal cancer - aged 49, a sister carries the BRCA1 gene and has been diagnosed with triple negative breast cancer aged 45. Father diagnosed with melanoma, 3 sisters with mutliple cases of BCC & SCC skin cancers. Patenal Side - Grandmother died of breast cancer aged 42. (no other details known on paternal side of family) Maternal side - Aunt dies of non hodgkin's lymphoma in her early 30's. Uncle dies of bowel cancer in his 50's. Grandfather dies of bowel cancer in his 70's. Cousin diagnosed with non hodgkin's lymphoma in his 30's. What is the likelihood of the remaining siblings in (2 brothers & 3 sisters) also being a carrier. I believe the risk of inheriting is 50% for every child born of a carrier, but what is the occurence. Given the strong family history of both paternal and maternal - Is it possible 6/6 will carry the BRAC1 (or any other cancer related gene)  

A fifth of US patients with melanoma being treated under the Medicare program wait more than 1.5 months before having the malignancy removed, and more than 8% wait longer than three months, a new study has found.  

A fifth of US patients with melanoma being treated under the Medicare program wait more than 1.5 months before having the malignancy removed, and more than 8% wait longer than three months, a new study has found.  

A drug approved to treat melanoma has proven effective for treating advanced nonsmall cell lung cancer in a new study - particularly for patients with high PD-L1 expression.  

Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, enters phase 3 and has opened enrollment of patients for its phase 3 international FDA...  

Giving the two immunotherapies ipilimumab and nivolumab simultaneously yielded better treatment responses than ipilimumab alone in patients with advanced melanoma who received no prior...  

Melanoma cells become drug resistant by using surrounding healthy cells to provide a 'safe haven' from treatment, according to new research published in Cancer Cell.  

Melanoma is an aggressive form of skin cancer that has been increasing in incidence in adults over the past 40 years.  

In a study that included more than 32,000 cases of melanoma among Medicare patients, approximately 1 in 5 experienced a delay of surgery that was longer than 1.  

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, has announced study results demonstrating that its DecisionDx-Melanoma™ gene expression profile...  

Cancer cell spread to the sentinel node - the lymph node to which cancer cells are most likely to spread from a primary tumor - is a risk factor for melanoma death.  

KU Leuven researchers have zeroed in on what makes cancer cells in melanoma so aggressive. They also succeeded in taming the effect in cell cultures.